<p><strong>目前無需股東採取行動</strong></p>
<p>佛羅里達州德爾雷海灘，2025 年 12 月 11 日（全球新聞通訊社）—— PetMed Express, Inc.，以 PetMeds 和 PetCareRx 的母公司名義運營（納斯達克：PETS）（“公司” 或 “PetMeds”），今天確認已收到來自新加坡投資公司 SilverCape Investments Limited 的非正式且不具約束力的收購提議，擬以每股 4 美元現金收購公司所有流通股份，受盡職調查和簽署雙方可接受的最終協議等多項條件的限制，但不受任何融資條件的限制。雖然 PetMeds 通常不會對私下提交的非正式收購提議公開評論，但 SilverCape 已在 2025 年 12 月 11 日向美國證券交易委員會提交的 Schedule 13D 修正案中公開披露了其提議及相關條款。</p>
<p>PetMeds 董事會將根據其信託責任，並在財務和法律顧問的協助下，仔細審查和考慮 SilverCape 的收購提議，以確定其認為符合 PetMeds 及其股東最佳利益的行動方案。PetMeds 指出，SilverCape 的信函並不構成可接受的正式報價，因此股東目前無需採取任何行動。</p>
<p><strong>關於 PetMed Express, Inc.</strong></p>
<p>PetMeds 成立於 1996 年，是直接面向消費者的寵物醫療保健領域的先驅。作為一家值得信賴的全國在線藥房，PetMeds 在所有 50 個州均持有執照，並配備了專注於支持寵物健康的專業藥劑師，服務於寵物及其主人，以及為他們提供服務的獸醫。通過其 PETS 品牌系列和 PetCareRx 子公司，公司提供全面的寵物健康解決方案——包括知名品牌和仿製藥、複合藥物以及更適合寵物的非處方補充劑和營養品。PetMeds 和 PetCareRx 專注於價值、便利和關懷，幫助寵物主人讓他們的狗、貓和馬過上更長、更健康的生活。欲瞭解更多信息，請訪問 www.PetMeds.com 和 www.PetCareRx.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的定義的前瞻性聲明。本新聞稿中所有與歷史事實無關的聲明應視為前瞻性聲明。諸如 “可能”、“可以”、“期望”、“預測”、“展望”、“戰略”、“打算”、“計劃”、“尋求”、“預期”、“相信”、“估計”、“預測”、“潛在”、“努力”、“目標”、“繼續”、“可能”、“將”、“會” 等類似詞彙和表達旨在表示前瞻性聲明。前瞻性聲明基於公司對未來事件的當前預期和假設，這些事件面臨風險和不確定性。由於多種因素，實際結果可能與預期結果有重大差異，包括但不限於公司董事會審計委員會現已完成的調查結果、公司截至 2025 年 6 月 30 日和 2025 年 9 月 30 日的季度報告在提交時可能比預期更長的風險，以及公司在證券交易委員會的文件中不時描述的其他風險，包括但不限於截至 2025 年 3 月 31 日的年度報告（Form 10-K）以及後續的 Form 10-Q 和定期的 Form 8-K 文件。您不應對這些前瞻性聲明過於依賴，這些聲明僅適用於本新聞稿的日期，並且不應被視為公司在任何後續日期的觀點。公司沒有義務更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，除非適用法律要求。</p>
<p><strong>投資者聯繫</strong></p>
<p>ICR, LLC</p>
<p>Reed Anderson</p>
<p>(646) 277-1260</p>
<p>investor@petmeds.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EYzROU00zTXpFM056QTBJekl3TVRnNU5UTT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EYzROU00zTXpFM056QTBJekl3TVRnNU5UTT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png"/></p>

PETS

<p>PetMed Express 收到了 SilverCape Investments Limited 提出的非正式、非約束性的收購提議，擬以每股 4 美元現金收購所有流通股份。該提議需滿足盡職調查和最終協議等條件。PetMed 的董事會將審查該提議，目前不需要股東採取任何行動。SilverCape 的提議並不是正式報價，PetMed 強調股東目前無需採取行動</p>

<p><strong>No Stockholder Action Required at this Time</strong></p>
<div class="lb-trans"><p><strong>目前無需股東採取行動</strong></p>
</div><p>DELRAY BEACH, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company” or “PetMeds”), today confirmed that it has received an unsolicited and non-binding acquisition proposal from SilverCape Investments Limited, a Singapore-based investment firm, to acquire all of the outstanding shares of the Company for $4 per share in cash, subject to various conditions such as due diligence and the execution of a mutually acceptable definitive agreement, but not subject to any financing contingency. While PetMeds would typically not publicly comment on privately submitted and non-binding acquisition proposals, SilverCape has publicly disclosed its proposal and the terms thereof in an amendment to its Schedule 13D that was filed with the U.S. Securities and Exchange Commission on December 11, 2025.</p>
<div class="lb-trans"><p>佛羅里達州德爾雷海灘，2025 年 12 月 11 日（全球新聞通訊社）—— PetMed Express, Inc.，以 PetMeds 和 PetCareRx 的母公司名義運營（納斯達克：PETS）（“公司” 或 “PetMeds”），今天確認已收到來自新加坡投資公司 SilverCape Investments Limited 的非正式且不具約束力的收購提議，擬以每股 4 美元現金收購公司所有流通股份，受盡職調查和簽署雙方可接受的最終協議等多項條件的限制，但不受任何融資條件的限制。雖然 PetMeds 通常不會對私下提交的非正式收購提議公開評論，但 SilverCape 已在 2025 年 12 月 11 日向美國證券交易委員會提交的 Schedule 13D 修正案中公開披露了其提議及相關條款。</p>
</div><p>The PetMeds Board of Directors, consistent with its fiduciary duties and in consultation with its financial and legal advisors, will carefully review and consider SilverCape’s acquisition proposal to determine the course of action that it believes is in the best interests of PetMeds and its stockholders. PetMeds notes that SilverCape’s letter does not constitute a formal offer capable of acceptance and, as such, stockholders do not need to take any action at this time.</p>
<div class="lb-trans"><p>PetMeds 董事會將根據其信託責任，並在財務和法律顧問的協助下，仔細審查和考慮 SilverCape 的收購提議，以確定其認為符合 PetMeds 及其股東最佳利益的行動方案。PetMeds 指出，SilverCape 的信函並不構成可接受的正式報價，因此股東目前無需採取任何行動。</p>
</div><p><strong>About PetMed Express, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 PetMed Express, Inc.</strong></p>
</div><p>Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.</p>
<div class="lb-trans"><p>PetMeds 成立於 1996 年，是直接面向消費者的寵物醫療保健領域的先驅。作為一家值得信賴的全國在線藥房，PetMeds 在所有 50 個州均持有執照，並配備了專注於支持寵物健康的專業藥劑師，服務於寵物及其主人，以及為他們提供服務的獸醫。通過其 PETS 品牌系列和 PetCareRx 子公司，公司提供全面的寵物健康解決方案——包括知名品牌和仿製藥、複合藥物以及更適合寵物的非處方補充劑和營養品。PetMeds 和 PetCareRx 專注於價值、便利和關懷，幫助寵物主人讓他們的狗、貓和馬過上更長、更健康的生活。欲瞭解更多信息，請訪問 www.PetMeds.com 和 www.PetCareRx.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events, which are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors, including but not limited to, the results of the now completed investigation by the Audit Committee of the Company’s Board of Directors, the risk that the completion of the filing of the Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 may take longer than expected, and other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的定義的前瞻性聲明。本新聞稿中所有與歷史事實無關的聲明應視為前瞻性聲明。諸如 “可能”、“可以”、“期望”、“預測”、“展望”、“戰略”、“打算”、“計劃”、“尋求”、“預期”、“相信”、“估計”、“預測”、“潛在”、“努力”、“目標”、“繼續”、“可能”、“將”、“會” 等類似詞彙和表達旨在表示前瞻性聲明。前瞻性聲明基於公司對未來事件的當前預期和假設，這些事件面臨風險和不確定性。由於多種因素，實際結果可能與預期結果有重大差異，包括但不限於公司董事會審計委員會現已完成的調查結果、公司截至 2025 年 6 月 30 日和 2025 年 9 月 30 日的季度報告在提交時可能比預期更長的風險，以及公司在證券交易委員會的文件中不時描述的其他風險，包括但不限於截至 2025 年 3 月 31 日的年度報告（Form 10-K）以及後續的 Form 10-Q 和定期的 Form 8-K 文件。您不應對這些前瞻性聲明過於依賴，這些聲明僅適用於本新聞稿的日期，並且不應被視為公司在任何後續日期的觀點。公司沒有義務更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，除非適用法律要求。</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫</strong></p>
</div><p>ICR, LLC</p>
<div class="lb-trans"><p>ICR, LLC</p>
</div><p>Reed Anderson</p>
<div class="lb-trans"><p>Reed Anderson</p>
</div><p>(646) 277-1260</p>
<div class="lb-trans"><p>(646) 277-1260</p>
</div><p>investor@petmeds.com</p>
<div class="lb-trans"><p>investor@petmeds.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EYzROU00zTXpFM056QTBJekl3TVRnNU5UTT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMDc4NSM3MzE3NzA0IzIwMTg5NTM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png"/></p>

PetMed Express 對 SilverCape Investments Limited 提出的未經請求且不具約束力的收購提案發表了評論 | PETS 股票新聞